Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndromeEmmanuel Raffoux, Hervé Dombret, Jean‐Valère Malfuson et al.|Oncotarget|2010Cited by 134
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemiaÉlise Fournier, Nicolas Boissel, Nicolas Duployez et al.|Blood|2019Cited by 87
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study resultsClaude Gardin, Hervé Dombret, Cécile Pautas et al.|Blood Advances|2020Cited by 84
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapyRaphaël Itzykson, Nicolas Duployez, Élise Fournier et al.|Blood|2021Cited by 64
Prognostic significance of concurrent gene mutations in intensively treated patients with<i>IDH</i>-mutated AML: an ALFA studyMatthieu Duchmann, Stéphane de Botton, Jean‐Baptiste Micol et al.|Blood|2021Cited by 63